1
|
Huguet F, Calvez ML, Benz N, Le Hir S, Mignen O, Buscaglia P, Horgen FD, Férec C, Kerbiriou M, Trouvé P. Function and regulation of TRPM7, as well as intracellular magnesium content, are altered in cells expressing ΔF508-CFTR and G551D-CFTR. Cell Mol Life Sci 2016; 73:3351-73. [PMID: 26874684 PMCID: PMC11108291 DOI: 10.1007/s00018-016-2149-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 01/14/2016] [Accepted: 01/25/2016] [Indexed: 02/03/2023]
Abstract
Cystic fibrosis (CF), one of the most common fatal hereditary disorders, is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The CFTR gene product is a multidomain adenosine triphosphate-binding cassette (ABC) protein that functions as a chloride (Cl(-)) channel that is regulated by intracellular magnesium [Mg(2+)]i. The most common mutations in CFTR are a deletion of a phenylalanine residue at position 508 (ΔF508-CFTR, 70-80 % of CF phenotypes) and a Gly551Asp substitution (G551D-CFTR, 4-5 % of alleles), which lead to decreased or almost abolished Cl(-) channel function, respectively. Magnesium ions have to be finely regulated within cells for optimal expression and function of CFTR. Therefore, the melastatin-like transient receptor potential cation channel, subfamily M, member 7 (TRPM7), which is responsible for Mg(2+) entry, was studies and [Mg(2+)]i measured in cells stably expressing wildtype CFTR, and two mutant proteins (ΔF508-CFTR and G551D-CFTR). This study shows for the first time that [Mg(2+)]i is decreased in cells expressing ΔF508-CFTR and G551D-CFTR mutated proteins. It was also observed that the expression of the TRPM7 protein is increased; however, membrane localization was altered for both ΔF508del-CFTR and G551D-CFTR. Furthermore, both the function and regulation of the TRPM7 channel regarding Mg(2+) is decreased in the cells expressing the mutated CFTR. Ca(2+) influx via TRPM7 were also modified in cells expressing a mutated CFTR. Therefore, there appears to be a direct involvement of TRPM7 in CF physiopathology. Finally, we propose that the TRPM7 activator Naltriben is a new potentiator for G551D-CFTR as the function of this mutant increases upon activation of TRPM7 by Naltriben.
Collapse
Affiliation(s)
- F Huguet
- Inserm, UMR1078, 46, rue Félix le Dantec, CS 51819, 29218, Brest Cedex 2, France
- Faculté de Médecine et des sciences de la santé, Université de Bretagne Occidentale, Brest, 29200, France
| | - M L Calvez
- Inserm, UMR1078, 46, rue Félix le Dantec, CS 51819, 29218, Brest Cedex 2, France
- Faculté de Médecine et des sciences de la santé, Université de Bretagne Occidentale, Brest, 29200, France
- Association G. Saleun, Brest, 29218, France
| | - N Benz
- Inserm, UMR1078, 46, rue Félix le Dantec, CS 51819, 29218, Brest Cedex 2, France
- Association G. Saleun, Brest, 29218, France
| | - S Le Hir
- Inserm, UMR1078, 46, rue Félix le Dantec, CS 51819, 29218, Brest Cedex 2, France
- Laboratoire de Génétique Moléculaire, Hôpital Morvan, C.H.U. Brest, Brest, 29200, France
| | - O Mignen
- Inserm, UMR1078, 46, rue Félix le Dantec, CS 51819, 29218, Brest Cedex 2, France
- Faculté de Médecine et des sciences de la santé, Université de Bretagne Occidentale, Brest, 29200, France
| | - P Buscaglia
- Inserm, UMR1078, 46, rue Félix le Dantec, CS 51819, 29218, Brest Cedex 2, France
- Faculté de Médecine et des sciences de la santé, Université de Bretagne Occidentale, Brest, 29200, France
| | - F D Horgen
- Laboratory of Marine Biological Chemistry, Department of Natural Sciences, Hawaii Pacific University, Kaneohe, HI, 96744, USA
| | - C Férec
- Inserm, UMR1078, 46, rue Félix le Dantec, CS 51819, 29218, Brest Cedex 2, France.
- Faculté de Médecine et des sciences de la santé, Université de Bretagne Occidentale, Brest, 29200, France.
- Laboratoire de Génétique Moléculaire, Hôpital Morvan, C.H.U. Brest, Brest, 29200, France.
- Etablissement Français du Sang - Bretagne, Brest, 29200, France.
| | - M Kerbiriou
- Inserm, UMR1078, 46, rue Félix le Dantec, CS 51819, 29218, Brest Cedex 2, France
- Faculté de Médecine et des sciences de la santé, Université de Bretagne Occidentale, Brest, 29200, France
| | - P Trouvé
- Inserm, UMR1078, 46, rue Félix le Dantec, CS 51819, 29218, Brest Cedex 2, France.
| |
Collapse
|
2
|
Trouvé P, Kerbiriou M, Teng L, Benz N, Taiya M, Le Hir S, Férec C. G551D-CFTR needs more bound actin than wild-type CFTR to maintain its presence in plasma membranes. Cell Biol Int 2015; 39:978-85. [PMID: 25712891 DOI: 10.1002/cbin.10456] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2014] [Revised: 02/23/2015] [Accepted: 02/23/2015] [Indexed: 12/16/2022]
Abstract
Cystic Fibrosis is due to mutations in the CFTR gene. The missense mutation G551D (approx. 5% of cases) encodes a CFTR chloride channel with normal cell surface expression but with an altered chloride channel activity, leading to a severe phenotype. Our aim was to identify specific interacting proteins of G551D-CFTR which could explain the channel defect. Wild-type CFTR (Wt-CFTR) was co-immunoprecipitated from stably transfected HeLa cells and resolved by 2D gel electrophoresis. Among the detected spots, one was expressed at a high level. Mass Spectrometry revealed that it corresponded to actin which is known to be involved in the CFTR's channel function. To assess whether actin could be involved in the altered G551D-CFTR function, its basal expression was studied. Because actin expression was the same in wt- and in G551D-CFTR expressing cells, its interaction with both wt- and G551D-CFTR was studied by co-immunoprecipitation, and we found that a higher amount of actin was bound onto G551D-CFTR than onto Wt-CFTR. The role of actin upon wt- and G551D-CFTR function was further studied by patch-clamp experiments after cytochalasin D treatment of the cells. We found a decrease of the very weak currents in G551D-CFTR expressing cells. Because a higher amount of actin is bound onto G551D-CFTR than onto Wt-CFTR, it is likely to be not involved in the mutated CFTR's defect. Nevertheless, because actin is necessary to maintain the very weak global currents observed in G551D-CFTR expressing HeLa cells, we conclude that more actin is necessary to maintain G551D-CFTR in the plasma membrane than for Wt-CFTR.
Collapse
Affiliation(s)
- Pascal Trouvé
- Inserm, UMR1078, Brest, F-29218, France.,Université de Bretagne Occidentale, Faculté de Médecine et des sciences de la santé, Brest, F-29200, France
| | - Mathieu Kerbiriou
- Inserm, UMR1078, Brest, F-29218, France.,Université de Bretagne Occidentale, Faculté de Médecine et des sciences de la santé, Brest, F-29200, France
| | - Ling Teng
- Inserm, UMR1078, Brest, F-29218, France.,Université de Bretagne Occidentale, Faculté de Médecine et des sciences de la santé, Brest, F-29200, France
| | - Nathalie Benz
- Inserm, UMR1078, Brest, F-29218, France.,Association de Biogénétique Gaëtan Salaün - Bretagne, Brest, F-29200, France
| | - Mehdi Taiya
- Service commun de spectrométrie de masse, Université de Bretagne Occidentale, Brest, F-29200, France
| | - Sophie Le Hir
- Inserm, UMR1078, Brest, F-29218, France.,C.H.U. Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire, Brest, F-29200, France
| | - Claude Férec
- Inserm, UMR1078, Brest, F-29218, France.,Université de Bretagne Occidentale, Faculté de Médecine et des sciences de la santé, Brest, F-29200, France.,C.H.U. Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire, Brest, F-29200, France.,Etablissement Français du Sang - Bretagne, Brest, F-29200, France
| |
Collapse
|
3
|
Merk D, Schubert-Zsilavecz M. Repairing mutated proteins – development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator. Expert Opin Drug Discov 2013; 8:691-708. [DOI: 10.1517/17460441.2013.788495] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
4
|
Abstract
With knowledge of the molecular behaviour of the cystic fibrosis transmembrane conductance regulator (CFTR), its physiological role and dysfunction in cystic fibrosis (CF), therapeutic strategies are now being developed that target the root cause of CF rather than disease symptoms. Here, we review progress towards the development of rational new therapies for CF. We highlight the discovery of small molecules that rescue the cell surface expression and defective channel gating of CF mutants, termed CFTR correctors and CFTR potentiators, respectively. We draw attention to alternative approaches to restore epithelial ion transport to CF epithelia, including inhibitors of the epithelial Na(+) channel (ENaC) and activators of the Ca(2+)-activated Cl(-) channel TMEM16A. The expertise required to translate small molecules identified in the laboratory to drugs for CF patients depends on our ability to coordinate drug development at an international level and our ability to provide pertinent biological information using suitable disease models.
Collapse
|
5
|
Melani R, Tomati V, Galietta LJV, Zegarra-Moran O. Modulation of cystic fibrosis transmembrane conductance regulator (CFTR) activity and genistein binding by cytosolic pH. J Biol Chem 2010; 285:41591-6. [PMID: 20974851 DOI: 10.1074/jbc.m110.166850] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Potentiators are molecules that increase the activity of the cystic fibrosis transmembrane conductance regulator (CFTR). Some potentiators can also inhibit CFTR at higher concentrations. The activating binding site is thought to be located at the interface of the dimer formed by the two nucleotide-binding domains. We have hypothesized that if binding of potentiators involves titratable residues forming salt bridges, then modifications of cytosolic pH (pH(i)) would alter the binding affinity. Here, we analyzed the effect of pH(i) on CFTR activation and on the binding of genistein, a well known CFTR potentiator. We found that pH(i) does modify CFTR maximum current (I(m)) and half-activation concentration (K(d)): I(m) = 127.7, 185.5, and 231.8 μA/cm(2) and K(d) = 32.7, 56.6 and 71.9 μm at pH 6, 7.35, and 8, respectively. We also found that the genistein apparent dissociation constant for activation (K(a)) increased at alkaline pH(i), near cysteine pK (K(a) = 1.83, 1.81 and 4.99 μm at pH(i) 6, 7.35, and 8, respectively), suggesting the involvement of cysteines in the binding site. Mutations of cysteine residues predicted to be within (Cys-491) or outside (Cys-1344) the potentiator-binding site showed that Cys-491 is responsible for the sensitivity of potentiator binding to alkaline pH(i). Effects of pH(i) on inhibition by high genistein doses were also analyzed. Our results extend previous data about multiple effects of pH(i) on CFTR activity and demonstrate that binding of potentiators involves salt bridge formation with amino acids of nucleotide-binding domain 1.
Collapse
Affiliation(s)
- Raffaella Melani
- Laboratorio di Genetica Molecolare, Istituto Giannina Gaslini, 16148 Genoa, Italy
| | | | | | | |
Collapse
|
6
|
Sun LR, Zhong JL, Cui SX, Li X, Ward SG, Shi YQ, Zhang XF, Cheng YN, Gao JJ, Qu XJ. Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells. Pharmacol Rep 2010; 62:333-42. [PMID: 20508289 DOI: 10.1016/s1734-1140(10)70273-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2009] [Revised: 10/21/2009] [Indexed: 10/25/2022]
Abstract
QA3 is a derivative of the substituted 1,3-dimethyl-1H-quinoxalin-2-ones, which are compounds that may selectively antagonize P-glycoprotein (P-gp) in multidrug resistance (MDR) cancer cells. Our previous work identified QA3 as a candidate compound for reversing MDR in cancer cells. In the present study, we found that QA3 significantly decreases the intracellular level of ATP, stimulates ATPase activity in membrane microsomes and decreases protein kinase C (PKC) activity. These results indicated that QA3 inhibits P-gp activity by blocking ATP hydrolysis and ATP regeneration. Furthermore, QA3 triggered and increased adriamycin-induced K562/A02 cell apoptosis as evidenced by Annexin V-FITC plus PI staining.Western blot analysis showed that the levels of cleaved caspase-9 and cleaved caspase-3 proteins increased, and similarly, the levels of procaspase-9 and procaspase-3 decreased after QA3 treatment. Consequently, poly ADP-ribose polymerase (PARP) activity increased as evidenced by the presence of the PARP cleavage product in K562/A02 cells. QA3 also enhanced the potency of adriamycin against K562/A02 cells as demonstrated by increased apoptosis and activation of caspase-9,-3 and PARP. These data support the observation that P-gp activity is inhibited after QA3 treatment. Moreover, these results indicate that QA3 is a novel MDR reversal agent with potent inhibitory action against P-gp MDR cancer cells.
Collapse
Affiliation(s)
- Li-Rui Sun
- Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, Jinan, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Daus ML, Grote M, Müller P, Doebber M, Herrmann A, Steinhoff HJ, Dassa E, Schneider E. ATP-driven MalK dimer closure and reopening and conformational changes of the "EAA" motifs are crucial for function of the maltose ATP-binding cassette transporter (MalFGK2). J Biol Chem 2007; 282:22387-96. [PMID: 17545154 DOI: 10.1074/jbc.m701979200] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
We have investigated conformational changes of the purified maltose ATP-binding cassette transporter (MalFGK(2)) upon binding of ATP. The transport complex is composed of a heterodimer of the hydrophobic subunits MalF and MalG constituting the translocation pore and of a homodimer of MalK, representing the ATP-hydrolyzing subunit. Substrate is delivered to the transporter in complex with periplasmic maltose-binding protein (MalE). Cross-linking experiments with a variant containing an A85C mutation within the Q-loop of each MalK monomer indicated an ATP-induced shortening of the distance between both monomers. Cross-linking caused a substantial inhibition of MalE-maltose-stimulated ATPase activity. We further demonstrated that a mutation affecting the "catalytic carboxylate" (E159Q) locks the MalK dimer in the closed state, whereas a transporter containing the "ABC signature" mutation Q140K permanently resides in the resting state. Cross-linking experiments with variants containing the A85C mutation combined with cysteine substitutions in the conserved EAA motifs of MalF and MalG, respectively, revealed close proximity of these residues in the resting state. The formation of a MalK-MalG heterodimer remained unchanged upon the addition of ATP, indicating that MalG-EAA moves along with MalK during dimer closure. In contrast, the yield of MalK-MalF dimers was substantially reduced. This might be taken as further evidence for asymmetric functions of both EAA motifs. Cross-linking also caused inhibition of ATPase activity, suggesting that transporter function requires conformational changes of both EAA motifs. Together, our data support ATP-driven MalK dimer closure and reopening as crucial steps in the translocation cycle of the intact maltose transporter and are discussed with respect to a current model.
Collapse
Affiliation(s)
- Martin L Daus
- Institut für Biologie/Bakterienphysiologie, Humboldt Universität zu Berlin, Chausseestrasse 117, D-10115 Berlin, Germany
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Melin P, Hosy E, Vivaudou M, Becq F. CFTR inhibition by glibenclamide requires a positive charge in cytoplasmic loop three. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES 2007; 1768:2438-46. [PMID: 17582383 DOI: 10.1016/j.bbamem.2007.05.013] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/20/2007] [Revised: 05/02/2007] [Accepted: 05/14/2007] [Indexed: 10/23/2022]
Abstract
The sulfonylurea glibenclamide is widely used as an open-channel blocker of the CFTR chloride channel. Here, we used site-directed mutagenesis to identify glibenclamide site of interaction: a positively charged residue K978, located in the cytoplasmic loop 3. Charge-neutralizing mutations K978A, K978Q, K978S abolished the inhibition of forskolin-activated CFTR chloride current by glibenclamide but not by CFTR(inh)-172. The charge-conservative mutation K978R did not alter glibenclamide sensitivity of CFTR current. Mutations of the neighbouring R975 (R975A, R975S, R975Q) did not affect electrophysiological and pharmacological properties of CFTR. No alteration of halide selectivity was observed with any of these CFTR mutant channels. This study identifies a novel potential inhibitor site within the CFTR molecule, and suggests a novel role of cytoplasmic loop three, within the second transmembrane domain of CFTR protein. This work is the first to report on the role of a residue in a cytoplasmic loop in the mechanism of action of the channel blocker glibenclamide.
Collapse
Affiliation(s)
- Patricia Melin
- Institut de Physiologie et Biologie Cellulaires, Université de Poitiers, CNRS UMR 6187, 86022 Poitiers cedex, France.
| | | | | | | |
Collapse
|